Fitaro vs. Ozempic vs. Wegovy: Comparing Semaglutide Treatments
Table of Contents
Fitaro, Ozempic, and Wegovy are three medications often discussed in the context of weight management and the treatment of type 2 diabetes. Understanding their differences is crucial for making informed decisions about your treatment options.
Here is a comprehensive guide on Fitaro vs. Ozempic vs. Wegovy. This guide describes how these three compare in clinical use, cost, efficacy and safety, and what factors should be considered while selecting one of them.
Ozempic
Ozempic (semaglutide) is a common medicine used to treat type 2 diabetes. It is also useful in reducing the risk of cardiovascular events, making it a dual-purpose drug in managing both diabetes and cardiovascular risk.
Wegovy
Wegovy is another formulation of Semaglutide, like Ozempic, but it is specifically approved for chronic weight management in adults with obesity or overweight conditions and having a comorbid condition like hypertension or type 2 diabetes.
Fitaro
Fitaro, though less widely known compared to Ozempic and Wegovy, represents a newer entry into the market of weight management and type 2 diabetes treatments. Like Ozempic and Wegovy, its active ingredient is also Semaglutide, a GLP-1 analog.
Clinical Use of Ozempic vs Wegovy vs Fitaro
1. Ozempic
Ozempic is an FDA approved drug to lower blood sugar levels in patients with type 2 diabetes mellitus (T2DM). It has also shown good results in lowering cardiovascular risks and thus, is also used to reduce the risk of cardiovascular events like cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in patients with and without T2DM and established cardiovascular disease.
2. Wegovy
It is FDA-approved for use in combination with diet and exercise to promote weight loss in obese people. It is also used for weight reduction in overweight people (BMI of 27 or more) who have a comorbid condition like hypertension or type 2 diabetes mellitus. Wegovy is the only Semaglutide formulation that is approved for use in children above the age of 12 years.
3. Fitaro
It is a newer formulation of Semaglutide and unlike Ozempic and Wegovy, a lot of studies have not been done on Fitaro. However, since it contains the same active ingredient (semaglutide) as Ozempic and Wegovy, it can be used to lower blood sugar levels in type 2 diabetics and weight in obese. It is not recommended to use in people below 18 years of age.
Conclusion
In conclusion, Ozempic is used for glycemic control and reduction of cardiovascular risk, Wegovy is approved for weight reduction in obese and overweight people, and Fitaro can be used for both, glycemic control and weight reduction. Only Wegovy is approved for use in children above 12 years of age.
-
Metformin Tablets
Metformin HCl 250mg / 500mg / 1g
Size: 60 tablets
Brand name: Glucophage, Glumetza, Riomet
From USD $15.00 Select options This product has multiple variants. The options may be chosen on the product page -
Rybelsus® Semaglutide Tablets
Semaglutide 3mg / 7mg / 14mg
Size: 30 Tablets
Brand name: Rybelsus, Ozempic, Wegovy
From USD $360.00 Select options This product has multiple variants. The options may be chosen on the product page -
Fitaro® Semaglutide Subcutaneous Injection
Semaglutide 0.25mg / 0.50mg / 1mg / 1.7mg / 2.4mg
Size: 1 Pre-Filled Injection Syringe
Brand name: Ozempic, Wegovy
From USD $162.00 Select options This product has multiple variants. The options may be chosen on the product page -
Slim Trim Active® Orlistat Capsules
Orlistat 60mg / 120mg
Size: 30 Capsules
Brand name: Alli, Xenical
From USD $38.00 Select options This product has multiple variants. The options may be chosen on the product page -
Victoza® Liraglutide Pre-Filled Pen
Liraglutide 6mg/ml Solution for Injection
Size: 3ml in 1 Pre-Filled Pen
Brand name: Saxenda
USD $231.00 Add to cart -
Saxenda® Liraglutide injection
Liraglutide 3mg
Size: 3ml / 0.10fl.oz in 1 Pre-Filled Pen
Brand name: Victoza
USD $190.00 Add to cart -
Jardiance® Empagliflozin Tablets
Empagliflozin 5mg / 10mg / 12.5mg / 25mg + Metformin 500mg / 1000mg
Size: 30 Tablets
Brand name: Jardiance
From USD $178.00 Select options This product has multiple variants. The options may be chosen on the product page
Efficacy of Ozempic vs Wegovy vs Fitaro
1. Ozempic
Ozempic has better effectiveness in lowering blood sugar levels and reducing cardiovascular risk than Wegovy and Fitaro.
2. Wegovy
Wegovy is more effectiveness in reducing weight in obese and overweight people than Ozempic and Fitaro.
3. Fitaro
Fitaro is a newer formulation and it can have nearly the same effectiveness as Ozempic in weight reduction and nearly the same effectiveness as Wegovy in glycemic control, if not better.
Conclusion
Ozempic is more effective for glycemic control and Wegovy is more effective for weight control. Fitaro may have equal or slightly less effectiveness than Ozempic and Wegovy.
Safety of Ozempic vs Wegovy vs Fitaro
All three medications, having the same active ingredient, have similar safety profile and side effects. Common side effects include:
- Hypoglycemia (low blood sugar)
- Pancreatitis (inflammation of the pancreas)
- Acute kidney injury
- Gall bladder problems
- Thyroid cancer
- Fatigue
- Headache
- Rash
- Hair loss (alopecia)
- Vitreous hemorrhage (bleeding in the eye) in patients with diabetic retinopathy
- Anxiety
- Dizziness
- Discomfort at the injection site
- Redness at the injection site
- Digestive issues
Cost of Ozempic vs Fitaro vs Wegovy
The cost comparison of Fitaro Semaglutide vs Ozempic and Fitaro vs Wegovy shows that Fitaro although potentially less effective, is much more affordable than Ozempic and Wegovy. Both Ozempic and Wegovy cost around $1000 or more per month. The cost of Fitaro is around $700 – $900 per month.
Considerations for Selecting a Treatment
The choice of Fitaro Semaglutide vs Ozempic vs Wegovy would depend on individual patient factors, including the primary treatment goal (glycemic control vs. weight loss), tolerability, and any pre-existing medical conditions.
For instance, patients who primarily want weight loss may prefer Wegovy because it is more effective for this purpose. Those with type 2 diabetes may benefit more from Ozempic because it is better at controlling blood sugar levels. For those who cannot easily afford Ozempic or Wegovy, Fitaro is a better option. In patients, where Semaglutide is contraindicated, other weight reduction methods like Jardiance can be used.
Frequently Asked Questions (FAQs) About Fitaro Semaglutide vs Ozempic vs Wegovy
1. What is the difference between Fitaro and Ozempic?
Fitaro and Ozempic are two different brand names of the same medicine Semaglutide, a GLP-1 agonist. Ozempic is approved for controlling blood sugar levels in type 2 diabetic patients and reducing the risk of cardiovascular events in patients with or without T2DM. Fitaro can also be used for these purposes as well as reducing weight in obese patients. Fitaro is much more affordable than Ozempic.
2. How does Fitaro compare to Wegovy?
Wegovy is better for weight reduction in obese people. Fitaro can be used for controlling blood sugar levels in patients with T2DM as well. Fitaro is also more affordable than Wegovy.
3. Is Fitaro the same as Ozempic?
The answer to the question “Is fitaro the same as Ozempic” is yes. Fitaro is same as Ozempic. Both contain semaglutide, a GLP-1 analog.
4. Which medicine is more effective for weight loss: Fitaro or Ozempic?
Many studies have not been done on Fitaro vs Ozempic but Ozempic may have slightly higher effectiveness than Fitaro in weight reduction. However, Fitaro is significantly more affordable than Ozempic.
5. What are the side effects of Fitaro compared to Ozempic?
Both Fitaro and Ozempic have the same effects including hypoglycemia, pancreatitis, acute kidney injury, gall bladder problems, thyroid cancer, fatigue, headache, rash, alopecia, vitreous haemorrhage in patients with diabetic retinopathy, anxiety, dizziness, discomfort at the injection site, redness at the injection site and gut problems.
References
- Kommu S, Whitfield P. Semaglutide. [Updated 2024 Feb 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603723/
- Smits, M. M., & Van Raalte, D. H. (2021). Safety of semaglutide. Frontiers in endocrinology, 12, 645563. https://doi.org/10.3389/fendo.2021.645563
- Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., … & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023). Semaglutide for the treatment of obesity. Trends in cardiovascular medicine, 33(3), 159-166. https://doi.org/10.1016/j.tcm.2021.12.008
Post by:
Dr.Marcella Jiovanni
Health and Beauty Expert
“Marcella Jiovanni actively promotes the importance of maintaining healthy skin, she envisions the future of dermatology as moving away from pure medical, pharmacological dermatology and flowing more toward a holistic approach to wellness and skincare.”